Pharma stock engaged in manufacturing, marketing, and distribution of medical products and medical education services to clinics, pharma, medical companies, and others jumped 2 percent in the day’s trade upon signing a distribution agreement to supply cardiovascular healthcare products.
Price Action
With a market capitalization of Rs. 223 Crores, the shares of QMS Medical Allied Services Limited were trading at Rs. 125 per equity share, up 2 percent from its previous day’s close price of Rs. 147.65.
What Happened
QMS Medical Allied Services Limited engaged in manufacturing, marketing, and distribution of medical products and many more has entered into a Distributor Agreement with Sahajanand Medical Technologies Limited and Vascular Concepts Limited.
The said agreement is for the distribution of a range of specialized cardiovascular healthcare products that will be supplied from the warehouses of QMS Medical Allied Services to the clients which will consist of hospitals & nursing homes. These products include cardiac stents, aortic balloon valves and other specialized products that will be used by healthcare professionals for the wellbeing of patients.
About the company
QMS Medical Allied Services Limited is engaged in manufacturing, marketing, and distribution of medical products and medical education services to clinics, pharma, medical companies, and also to individual users.
Financials and Ratios
Its revenue from operations grew by 17.39 percent from Rs. 104 Crores in FY23 to Rs. 122 Crores in FY24, accompanied by profits of Rs. 6 Crores to Rs. 9 Crores.
In terms of Return ratios, it has reported a return on equity (ROE) of 12.1 percent, and a return on capital employed (ROCE) of 14.7 percent. It has reported a debt-to-equity ratio of 0.44.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
